The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A novel Vertex Pharmaceuticals drug that takes a new approach to pain is now approved by the FDA, a landmark decision for a first-in-class product that brings patients a treatment alternative ...

The journey was fittingly excruciating. Pain, as Vertex Pharmaceuticals found out, is wildly complex. It starts simple enough, with a sliced hand or burned finger or broken bone. But it convolutes ...

Vertex Pharmaceuticals via AP The average time to meaningful pain relief ranged from two to four hours, compared to eight hours in the placebo group. Journavx works by inhibiting the NaV1.8 pain ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential.

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has given his Buy rating due to a combination of factors ...

With patents ... Vertex's push beyond CF, where years of investment are finally bearing fruit. All eyes are on Jan. 30, when the FDA weighs in on suzetrigine -- a potential game-changer for pain ...

Shares of Vertex ... pain, could limit annual sales to around $1.5 billion by 2030. Adding around $1.5 billion in annual sales by 2030 would be a step in the right direction for Vertex ...

Notably, Vertex Pharmaceuticals (NASDAQ ... already set to rake in approximately $10.9 billion last year. With patents locked up into the 2030s and rivals nowhere in sight, Vertex's CF fortress ...